Affimed (NASDAQ:AFMD) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Affimed (NASDAQ:AFMD) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $10.00 target price on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research note on Monday, September 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.00.

Affimed Stock Down 4.7 %

AFMD traded down $0.17 during trading on Friday, reaching $3.48. The stock had a trading volume of 132,609 shares, compared to its average volume of 266,981. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.71 and a quick ratio of 2.71. The stock’s 50 day moving average is $3.49 and its two-hundred day moving average is $4.52. Affimed has a one year low of $2.92 and a one year high of $8.95.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.67 million. On average, analysts expect that Affimed will post -4.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC increased its holdings in Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares in the last quarter. Choreo LLC bought a new position in Affimed during the second quarter valued at approximately $54,000. Intellectus Partners LLC boosted its holdings in Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,250 shares during the last quarter. Jane Street Group LLC purchased a new stake in Affimed in the third quarter worth approximately $44,000. Finally, Point72 Asset Management L.P. grew its position in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares during the period. 30.82% of the stock is owned by institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.